PRECIPIO INC (PRPO) Stock Price & Overview

NASDAQ:PRPOUS74019L6020

Current stock price

27.88 USD
+0.95 (+3.53%)
At close:
27.88 USD
0 (0%)
After Hours:

The current stock price of PRPO is 27.88 USD. Today PRPO is up by 3.53%. In the past month the price increased by 9.94%. In the past year, price increased by 311.21%.

PRPO Key Statistics

52-Week Range3.9 - 29.5299
Current PRPO stock price positioned within its 52-week range.
1-Month Range22.31 - 29.5299
Current PRPO stock price positioned within its 1-month range.
Market Cap
48.79M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.83
Dividend Yield
N/A

PRPO Stock Performance

Today
+3.53%
1 Week
+3.80%
1 Month
+9.94%
3 Months
+25.64%
Longer-term
6 Months +67.05%
1 Year +311.21%
2 Years +316.12%
3 Years +109.94%
5 Years -39.65%
10 Years N/A

PRPO Stock Chart

PRECIPIO INC / PRPO Daily stock chart

PRPO Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to PRPO. When comparing the yearly performance of all stocks, PRPO is one of the better performing stocks in the market, outperforming 98.71% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

PRPO Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to PRPO. While PRPO seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PRPO Earnings

Next Earnings DateMay 12, 2026
Last Earnings DateFeb 23, 2026
PeriodQ3 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

PRPO Forecast & Estimates


Analysts
Analysts82.86
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

PRPO Groups

Sector & Classification

Index Membership

PRPO Financial Highlights

Over the last trailing twelve months PRPO reported a non-GAAP Earnings per Share(EPS) of -0.83. The EPS increased by 59.49% compared to the year before.


Income Statements
Revenue(TTM)22.80M
Net Income(TTM)-1.25M
Industry RankSector Rank
PM (TTM) N/A
ROA -5.93%
ROE -9.12%
Debt/Equity 0.06
Chartmill High Growth Momentum
EPS Q2Q%88.6%
Sales Q2Q%29.91%
EPS 1Y (TTM)59.49%
Revenue 1Y (TTM)30.95%

PRPO Ownership

Ownership
Inst Owners17.46%
Shares1.75M
Float1.54M
Ins Owners12.11%
Short Float %0.23%
Short Ratio0.23

About PRPO

Company Profile

PRPO logo image Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. The company is headquartered in New Haven, Connecticut and currently employs 54 full-time employees. The company went IPO on 2000-07-18. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.

Company Info

IPO: 2000-07-18

PRECIPIO INC

4 Science Park

New Haven CONNECTICUT 06511 US

CEO: Ilan Danieli

Employees: 57

PRPO Company Website

PRPO Investor Relations

Phone: 12037877888

PRECIPIO INC / PRPO FAQ

What does PRPO do?

Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. The company is headquartered in New Haven, Connecticut and currently employs 54 full-time employees. The company went IPO on 2000-07-18. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.


Can you provide the latest stock price for PRECIPIO INC?

The current stock price of PRPO is 27.88 USD. The price increased by 3.53% in the last trading session.


Does PRECIPIO INC pay dividends?

PRPO does not pay a dividend.


What is the ChartMill rating of PRECIPIO INC stock?

PRPO has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is PRECIPIO INC worth?

PRECIPIO INC (PRPO) has a market capitalization of 48.79M USD. This makes PRPO a Nano Cap stock.


Who owns PRECIPIO INC?

You can find the ownership structure of PRECIPIO INC (PRPO) on the Ownership tab.


What is the Short Interest ratio of PRECIPIO INC (PRPO) stock?

The outstanding short interest for PRECIPIO INC (PRPO) is 0.23% of its float.